Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Bevacizumab vs Chemotherapy +/- Bevacizumab in Advanced Ovarian Clear Cell Carcinoma
NCT07002346Phase 3Recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in ovarian clear cell carcinoma (OCCC), sponsored by Tongji Hospital. Started Nov 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT07002346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002346.